1-13 of 13
Rodrigo Dienstmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

Helena Verdaguer, Tamara Saurí, Daniel Alejandro Acosta, Magdalena Guardiola, Alexandre Sierra, Jorge Hernando, Paulo Nuciforo, Josep M. Miquel, Cristina Molero, Sandra Peiró, Queralt Serra-Camprubí, Guillermo Villacampa, Susana Aguilar, Ana Vivancos, Josep Tabernero, Rodrigo Dienstmann, Teresa Macarulla
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1662–1671.
https://doi.org/10.1158/1078-0432.CCR-21-2384
Published: 14 April 2022
View article titled, ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
Open the PDF for ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 137–149.
https://doi.org/10.1158/1078-0432.CCR-21-1810
Published: 05 January 2022
View article titled, High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Open the PDF for High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer

Adam Lafferty, Alice C. O'Farrell, Giorgia Migliardi, Niraj Khemka, Andreas U. Lindner, Francesco Sassi, Eugenia R. Zanella, Manuela Salvucci, Evy Vanderheyden, Elodie Modave, Bram Boeckx, Luise Halang, Johannes Betge, Matthias P.A. Ebert, Patrick Dicker, Guillem Argilés, Josep Tabernero, Rodrigo Dienstmann, Enzo Medico, Diether Lambrechts, Andrea Bertotti, Claudio Isella, Livio Trusolino, Jochen H.M. Prehn, Annette T. Byrne
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5979–5992.
https://doi.org/10.1158/1078-0432.CCR-21-0818
Published: 01 November 2021
View article titled, Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer
Open the PDF for Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity

Jarle Bruun, Kushtrim Kryeziu, Peter W. Eide, Seyed H. Moosavi, Ina A. Eilertsen, Jonas Langerud, Bård Røsok, Max Z. Totland, Tuva H. Brunsell, Teijo Pellinen, Jani Saarela, Christian H. Bergsland, Hector G. Palmer, Kristoffer W. Brudvik, Tormod Guren, Rodrigo Dienstmann, Marianne G. Guren, Arild Nesbakken, Bjørn Atle Bjørnbeth, Anita Sveen, Ragnhild A. Lothe
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 4107–4119.
https://doi.org/10.1158/1078-0432.CCR-19-3637
Published: 03 August 2020
View article titled, Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Open the PDF for Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza, Cristina Viaplana, Analia Azaro, Maria Vieito, Irene Braña, Gemma Mur, Javier Ros, Jose Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, Maria Alsina, Elena Elez, Ana Oaknin, Eva Muñoz-Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Perez-Lopez, Elena Garralda
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (8): 1846–1855.
https://doi.org/10.1158/1078-0432.CCR-19-2226
Published: 15 April 2020
View article titled, Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Open the PDF for Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria in another window
Includes: Supplementary data
Journal Articles

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

David Tamborero, Carlota Rubio-Perez, Ferran Muiños, Radhakrishnan Sabarinathan, Josep M. Piulats, Aura Muntasell, Rodrigo Dienstmann, Nuria Lopez-Bigas, Abel Gonzalez-Perez
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3717–3728.
https://doi.org/10.1158/1078-0432.CCR-17-3509
Published: 31 July 2018
View article titled, A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Open the PDF for A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations in another window
Includes: Supplementary data
Journal Articles

Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer

Rodrigo Dienstmann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 989–990.
https://doi.org/10.1158/1078-0432.CCR-17-3477
Published: 28 February 2018
View article titled, Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer
Open the PDF for Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer in another window
Journal Articles

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

Anita Sveen, Jarle Bruun, Peter W. Eide, Ina A. Eilertsen, Lorena Ramirez, Astrid Murumägi, Mariliina Arjama, Stine A. Danielsen, Kushtrim Kryeziu, Elena Elez, Josep Tabernero, Justin Guinney, Hector G. Palmer, Arild Nesbakken, Olli Kallioniemi, Rodrigo Dienstmann, Ragnhild A. Lothe
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (4): 794–806.
https://doi.org/10.1158/1078-0432.CCR-17-1234
Published: 14 February 2018
View article titled, Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Open the PDF for Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies in another window
Includes: Supplementary data
Journal Articles

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P. Tenbaum, Guillem Argilés, Rodrigo Dienstmann, Natalia Fernández, Ginevra Caratù, Judit Matito, Daniel Silberschmidt, Jordi Rodon, Stefania Landolfi, Aleix Prat, Eloy Espín, Ramón Charco, Paolo Nuciforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Héctor G. Palmer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 644–656.
https://doi.org/10.1158/1078-0432.CCR-14-3081
Published: 31 January 2016
View article titled, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Open the PDF for Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5499–5510.
https://doi.org/10.1158/1078-0432.CCR-14-3091
Published: 14 December 2015
View article titled, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer
Open the PDF for MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Dejan Juric, Rodrigo Dienstmann, Andres Cervantes, Manuel Hidalgo, Wells Messersmith, George R. Blumenschein, Jr, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2462–2470.
https://doi.org/10.1158/1078-0432.CCR-14-2412
Published: 31 May 2015
View article titled, Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Open the PDF for Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors in another window
Journal Articles

TGR Analysis in Phase I Clinical Trials—Letter

Rodrigo Dienstmann, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2495–2496.
https://doi.org/10.1158/1078-0432.CCR-13-3455
Published: 30 April 2014
View article titled, TGR Analysis in Phase I Clinical Trials—Letter
Open the PDF for TGR Analysis in Phase I Clinical Trials—Letter in another window